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        Many pathogenic organisms, including viruses, 
have developed strategies to evade the host im-
mune system based on interference with host 
cytokine and chemokine proinfl  ammatory me-
diators (  1  –  3  ). Inhibitory binding proteins for 
proinflammatory cytokines, including TBP, 
IFNAR, and IL-18 BP, have also been described 
in humans, but no secreted chemokine binding 
proteins (CHPBs) have so far been identifi  ed 
in vertebrates. However, internal and external 
parasites have evolved chemokine neutraliza-
tion strategies that allow them to productively 
suppress the mammalian immune response to 
prolong survival on their host. Ticks are blood-
sucking parasites whose role in the transmission 
of pathogens such as   Borrelia burgdorferi  , which 
causes Lyme disease, has been the subject of 
intensive research (  4  ). Ticks feed on their hosts 
for relatively long periods of time, ranging 
from several days to weeks, and provided that 
they do not carry infectious agents, can re-
main essentially undetected by their hosts. To 
achieve this, they have evolved an arsenal of 
antiinfl  ammatory, anticoagulant, and analgesic 
agents that are used to render the ticks invis-
ible to the immune system (  5  ). Little is known 
about the molecular nature of such agents, but 
the cloning and characterization of these factors 
may shed light on the immunoevasion mecha-
nisms used by these organisms, as well as yield 
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  Bloodsucking parasites such as ticks have evolved a wide variety of immunomodulatory 
proteins that are secreted in their saliva, allowing them to feed for long periods of time 
without being detected by the host immune system. One possible strategy used by ticks to 
evade the host immune response is to produce proteins that selectively bind and neutralize 
the chemokines that normally recruit cells of the innate immune system that protect the 
host from parasites. We have identifi  ed distinct cDNAs encoding novel chemokine binding 
proteins (CHPBs), which we have termed Evasins, using an expression cloning approach. 
These CHBPs have unusually stringent chemokine selectivity, differentiating them from 
broader spectrum viral CHBPs. Evasin-1 binds to CCL3, CCL4, and CCL18; Evasin-3 binds to 
CXCL8 and CXCL1; and Evasin-4 binds to CCL5 and CCL11. We report the characterization 
of Evasin-1 and -3, which are unrelated in primary sequence and tertiary structure, and 
reveal novel folds. Administration of recombinant Evasin-1 and -3 in animal models of 
disease demonstrates that they have potent antiinfl  ammatory properties. These novel 
CHBPs designed by nature are even smaller than the recently described single-domain 
antibodies (Hollinger, P., and P.J. Hudson. 2005.   Nat. Biotechnol  . 23:1126–1136), and may 
be therapeutically useful as novel antiinfl  ammatory agents in the future. 
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published data). The possibility that the inhibition was caused 
by degradation of the radiolabeled chemokines by a proteo-
lytic activity in the saliva was addressed by incubation of the 
radiolabeled chemokines in saliva for 4 h. Subsequent analysis 
by SDS-PAGE revealed that no degradation of the chemo-
kine had occurred (unpublished data). We next addressed the 
question of whether there was more than one binding pro-
tein present in the saliva by testing whether an excess of 
CXCL8 was able to block the activity of the CCL3 binding 
protein. As shown in   Fig. 1 a  , a 500-fold excess of CXCL8 
had no eff  ect on the ability of the saliva to inhibit CCL3 
binding to CCR5, therefore suggesting the presence of at 
least two binding proteins. 
  Incubation of   125  I-CCL3 with tick saliva, followed by 
chemical cross-linking, produces a clear band shift when the 
reaction products were analyzed on SDS PAGE, and this 
method was adopted as a screening assay in our attempts to 
clone the tick CHBPs. We therefore used the band shift assay 
to screen supernatants from HEK293 cells transfected with 
a tick salivary gland cDNA library, to identify a cDNA en-
coding Evasin-1 (  11  ). Surface plasmon resonance (SPR) per-
formed with immobilized CCL3 and CCL5 demonstrated 
the presence of binding proteins for these two chemokines 
in tick saliva (  Fig. 1 b  ), and surface enhanced laser desorp-
tion ionization (SELDI) identifi  ed peaks that bound to im-
mobilized CXCL8 and CCL5 (  Fig. 1 c  ), but surprisingly, no 
peak was observed for CCL3 (not depicted). The masses 
identifi  ed by SELDI indicated very small proteins with a mass 
of 7,133 Daltons binding to CXCL8 and a mass of 11,052 
Daltons binding to CCL5; these masses are very close to 
those of the predicted protein cores, as discussed in the fol-
lowing section. 
  We therefore rescreened the cDNA library using a cocktail 
of chemokines and cytokines, containing iodinated CXCL8, 
IL-1     , and IL-2. IL-2 was included because an anti-IL-2 ac-
tivity has previously been reported in tick salivary gland ex-
tracts (  9  ). In the fi  rst round of screening, we identifi  ed a band 
shift in one pool of 270 clones. After deconvolution of the 
positive pool, and cross-linking to the individual iodinated 
proteins present in the cocktail, we identifi  ed a cDNA encod-
ing a CXCL8 binding protein. As we had previously identi-
fi  ed a putative CHBP that we named Evasin-2, the function 
of which remains to be elucidated, we called the CXCL8 bind-
ing protein Evasin-3 (  Fig. 2 a  , lane 3).   Competition experi-
ments using a panel of chemokines (CCL3, CXCL1, CXCL4, 
CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, 
and CXCL13) indicated that only CXCL1 and CXCL8 
were able to compete with radiolabeled CXCL8 for binding 
to Evasin-3 (unpublished data). We then screened the ex-
pression library with a second cocktail consisting of iodinated 
CCL5, CCL11, and CXCL10. Upon analysis of supernatants 
from HEK cells transfected with the pools of clones from the 
cDNA expression library, we observed a band shift migrating 
at     50 kD in several pools. This band was almost masked by 
a nonspecifi  c band migrating at     60 kD detected in all exper-
iments. Deconvolution of the positive pools revealed a cDNA 
novel proteins of potential therapeutic use in human infl  am-
matory pathologies. 
  Successful prevention of the activity of families of small 
chemoattractant proteins called chemokines has been shown 
for several viral CHBPs (for reviews see [  1, 6  ]), and, more 
recently, by a CHBP isolated from the parasitic worm   Schis-
tosoma mansoni   (  7  ). Deletion of the gene encoding the broad 
spectrum CHPB T1 from the rabbit poxvirus myxoma virus 
resulted in extensive leukocyte infi  ltration in the dermis of 
the infected animal, which was absent upon infection by the 
wild-type virus (  8  ). This study clearly demonstrated that the 
virus had evolved a mechanism that prevented the recruit-
ment of leukocytes to the site of infection. 
  Recently, the presence of antichemokine activities has 
been reported in tick saliva (  9, 10  ). Tick salivary gland ex-
tracts were shown to contain an activity that neutralized 
CXCL8, and in a later study, neutralization of other chemo-
kines was also demonstrated. Our own analyses of tick saliva 
harvested during feeding also demonstrated the presence of 
molecules that bound to CXCL8, CCL3, and CCL5. Using 
an expression cloning strategy to identify the protein(s) in tick 
saliva that bind to chemokines, we cloned a CHPB, which 
we called Evasin-1, that specifi  cally binds to the CC chemo-
kines CCL3, CCL4, and CCL18 (  11  ). We also cloned a sec-
ond protein of similar size, Evasin-2, for which the ligand 
remains to be elucidated. Subsequent rescreening of the tick 
salivary gland cDNA library with a selection of chemokines 
and cytokines enabled us to identify two further CHBPs. In 
this study, we report the cloning of a CXC CHPB named 
Evasin-3 and a second CC CHPB, distinct from Evasin-1, 
named Evasin-4. Interestingly, Evasin-3 bears no sequence 
homology to Evasin-1 and -4, which appear to belong to the 
same structural family. The three proteins are all surprisingly 
small compared with other chemokine and cytokine binding 
proteins described to date. Evasin-1 and -3 were crystallized, 
and their three-dimensional structures have been solved, re-
vealing novel folds with binding modes distinct from that of 
viral CHBPs. Investigations of their specifi  city in vitro and 
their effi   cacy in vivo in animal models of chronic infl  amma-
tory diseases such as pulmonary fi  brosis, arthritis, and psoriasis 
have demonstrated that the Evasins have potent antiinfl  am-
matory activities, providing tantalizing new insights into scaf-
folds evolved by nature to inhibit infl  ammation. 
    RESULTS   
  Evidence for the presence of CHPBs in tick saliva and their 
expression cloning 
  We analyzed the ability of saliva from   Rhipicephalus sanguineus   
(common brown dog tick) to inhibit the binding of the I  125  -
labeled chemokines CCL2, CCL5, and CXCL8, as well as 
CCL3, to their respective receptors using a scintillation prox-
imity assay. As shown in   Fig. 1 a  , inhibition of binding was 
achieved for CCL3, CCL5, and CXCL8, with the most po-
tent eff  ect on CCL3.   No inhibition was observed for CCL2 
although saliva harvested from another tick species,   Ambly-
omma cajennense  , appeared to have anti-CCL2 activity (un-JEM VOL. 205, September 1, 2008 
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identity at the primary sequence level, is well known in pro-
tein families such as cytokines and chemokines. 
  Transient expression of C-terminal 6His tagged Evasin-3 
and -4 in HEK293 cells revealed that unlike Evasin-1, these 
two proteins were poorly secreted. We were able to obtain a 
small amount of purifi  ed Evasin-3 (150   μ  g), which was exten-
sively glycosylated for in vitro characterization. SPR analysis 
revealed that Evasin-3, similar to Evasin-1, is a highly selective 
CHPB in that it was only able to bind to CXCL1 and CXCL8 
and their murine counterparts, KC and MIP-2 (  Fig. 2 c  ). The 
kinetic parameters, as determined by SPR, are shown in   Table I  .   
It has proven diffi   cult to produce recombinant 6His-tagged 
Evasin-4 in HEK293 cells, thus the identifi  cation of the N 
terminus of the mature protein has not yet been experimen-
tally verifi  ed. Using the Signal P program to predict the cleav-
age site of the putative signal peptide sequence indicates that 
the mature protein sequence would commence with WL-
STKC (  Fig. 2 b  ). However, secondary structure predictions 
show that these amino acids are contained in a helix, suggest-
ing that signal peptide cleavage may in fact be after Cys23, 
yielding an N terminus of EVPQM, as predicted by the latest 
version of Signal P. Nevertheless, alignment of the amino acid 
clone that was able to mediate cross-linking to both CCL5 
and CCL11 (  Fig. 2 a  , lanes 4 and 5), but not CXCL10 when 
tested in HEK293 cells. The CCL5 and CCL11 binding pro-
tein was named Evasin-4. 
  Structural analyses of the Evasins 
  The cDNA for Evasin-3 encoded an ORF of 92 amino ac-
ids that, after signal peptide cleavage, gave rise to a mature 
protein of 66 amino acids with a predicted molecular mass 
of 7,005 Daltons. The cDNA for Evasin-4 encoded an ORF 
of 117 amino acids. Cleavage of the signal peptide sequence 
predicted that using the Signal P algorithm would generate a 
mature protein of 110 amino acids with a predicted molecu-
lar mass of 12,032 Daltons (  Fig. 2 b  ). Analyses of the amino 
acid sequences of Evasin-3 and -4 revealed that Evasin-3 was 
unrelated to Evasin-1, whereas the Cys residues of the mature 
Evasin-4 sequence demonstrated an almost perfect alignment 
with those of Evasin-1 (  Fig. 2 b  ). This indicates an identi-
cal disulfi  de topology, suggesting that these two proteins are 
structurally related, despite their relatively low level of iden-
tity at the amino acid level (27% identity over 91 amino acids). 
Conservation of a homologous fold, despite a low level of 
    Figure 1.         Chemokine binding activity in tick saliva.   (a) Tick saliva inhibits the binding of CCL3, CCL5, and CXCL8 to their cognate receptors. Radiola-
beled chemokines were incubated with CHO cell membranes expressing CCR1 for CCL3 and CCL5, and CXCR2 for CXCL8, in the presence of 1   μ  l, 10   μ  l, or 
in the absence of tick saliva. The antichemokine activity is caused by the presence of more than one binding protein because an excess of CXCL8 did not 
abolish the inhibition of CCL3 binding. Error bars represent the mean   ±   SEM. (b) Detection of CHPBs in tick saliva by SPR. Sensograms demonstrated bind-
ing to CCL5(E66A) and CCL3 immobilized on a CM4 chip. (c) Detection of distinct CHPBs to CCL5 and CXCL8 by Retentate chromatography SELDI of fl  ight 
mass spectrometry (RC-SELDI-TOF-MS). Tick saliva was incubated on a PS-20 Proteinchip array coated with either CCL5 (bottom), CXCL8 (middle), or the 
control protein equine myoglobin (top). Specifi  c peaks, indicated by arrows, corresponding to a protein with a mass of 11,052 Daltons binding to CCL5 
and of 7,133 Daltons for the binding to CXCL8 were observed.     2022 ANTIINFLAMMATORY SELECTIVE CHEMOKINE BINDING PROTEINS   | D  é  ruaz et al. 
be directed into inclusion bodies based on a formula predict-
ing solubility for recombinant expression in   E. coli   (  12  ). Sur-
prisingly, the protein was expressed at high levels as soluble 
protein that could be purifi  ed to homogeneity in two chro-
matographic steps (unpublished data). Although the protein 
produced in   E. coli   is not glycosylated, it had equivalent ac-
tivity to Evasin-3 produced in HEK293 cells (  Table I  ; see 
also   Fig. 8 a  ), suggesting that the glycosylation was not essen-
tial for activity. 
sequences of Evasin-4 and -1 still shows that Evasin-4 has an 
extended N terminus compared with Evasin-1, which may be 
an important determinant of ligand binding specifi  city. We 
are currently testing diff  erent expression strategies to obtain 
suffi   cient Evasin-4 for N-terminal sequence verifi  cation and 
for in vitro and in vivo studies. 
  Because the yield of Evasin-3 was poor in the HEK293 
expression system, we attempted expression in a prokaryotic 
host,   Escherichia coli.   It was very probable that Evasin-3 would 
    Figure 2.         Identifi  cation of Evasin-3 and -4.   (a)  Identifi  cation of Evasin-3 and -4 by cross-linking to radiolabeled chemokine in supernatants 
from transfected HEK293 cells. Viral CHBP p35 incubated with [  125  I]-CCL2 as a positive control in the presence (lane 1) or absence (lane 2) of the 
cross-linker BS  3  ; supernatant from clone 69.19.1 incubated with [  125  I]-CXCL8 and BS  3   (lane 3); supernatant from clone 10.27.1 incubated with [  125 I]-
CCL5 and BS  3   (lane 4) or [  125  I]-CCL11 and BS  3   (lane 5). (b) Alignment of the predicted protein sequences of Evasin-1 and -4. Conserved residues are 
highlighted in gray and cysteines are shown in bold type. The predicted protein sequence of Evasin-3 is shown below the alignment. The signal pep-
tides are shown in italics. Possible signal peptides of Evasin-4 are shown as follows: based on SignalJ prediction, black underline; based on secondary 
structure prediction, dotted underline; based on similarity to Evasin-1, dashed line. (c) Determination of the selectivity of immobilized recombinant 
Evasin-3 produced in   E. coli   by surface plasmon resonance. Sensograms corresponding to CXCL8 (bold black lines) CXCL1 (dotted black lines), MIP-2 
(gray lines), and KC (dotted gray lines) showed strong binding of these chemokines to Evasin-3. The sensograms corresponding to CCL1, CCL2, CCL3, 
CCL4, CCL5, CCL11, CCL18, CCL27, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, and CX  3  CL1 (black lines) indicated no binding of these chemokines 
to Evasin-3.     
    Table I.        Binding characteristics of Evasin-1 and -3 as determined by SPR 
CKBP Chemokine k  a     ×   10  6  k  d     ×   10      3 K  d     ×   10      9 
M  -1  s  -1 s  -1 nM
Evasin-1 CCL3 13.8   ±   3.54 2.43   ±   0.61 0.12
CCL3L1 13.2   ±   2.9 0.67   ±   0.13 0.05
mMIP-1     15.6   ±   16 1.18   ±   1.07 0.08
CCL4 4.29   ±   2.58 2.2   ±   0.18 0.51
mMIP-1     3.84   ±   1.42 0.58   ±   0.12 0.15
Evasin-3 (HEK) CXCL1 3.95   ±   4.23 1.42   ±   0.36 0.34
CXCL8 0.41   ±   0.30 0.29   ±   0.14 0.7
KC 0.64   ±   0.58 1.44   ±   0.35 2.25
MIP-2 0.79   ±   0.9 0.33   ±   0.11 0.4
Evasin-3 (  E. coli  ) CXCL1 2.61   ±   0.69 2.22   ±   0.49 0.85
CXCL8 0.84   ±   0.33 0.36   ±   0.05 0.43
KC 0.32   ±   0.17 1.85   ±   0.43 5.78
MIP-2 1.02   ±   0.56 0.65   ±   0.25 0.64JEM VOL. 205, September 1, 2008 
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  The IC  50   values reported for the inhibition of receptor 
binding, 0.015 nM for CCL3 binding to CCR1 and 3 nM 
for CCL4 binding to CCR5 (  11  ), are refl  ected by the ability 
of Evasin-1 to inhibit the chemotactic activity of these chemo-
kines in vitro and in vivo. We chose the L1.2/CCR5 trans-
fectants for these analyses because we were able to test 
inhibition of CCL3, CCL3L1, the high-affi   nity variant for 
this receptor, and CCL4 in the same assay system. As shown 
in   Fig. 4 a  , Evasin-1 showed potent inhibition of ligand-
  induced chemotaxis of the L1.2/CCR5 transfectants.   Using 
an ED  80   ligand concentration of 1 nM for CCL3L1 and CCL4, 
and 10 nM for CCL3, the IC  50   values were 0.17 nM for 
CCL3L1, 2 nM for CCL3, and 4 nM for CCL4. 
  We then tested Evasin-1 in in vivo leukocyte recruitment 
models in mice. CCL3 and murine MIP-1      were adminis-
tered into the peritoneal cavity, and the ability of systemically 
administered Evasin-1 to block leukocyte recruitment was 
  Evasin-3 produced in   E. coli   crystallized readily, and the 
structure revealed a novel fold that was totally unrelated to 
that of Evasin-1 (  Fig. 3  ).   The crystallographic structure of 
Evasin-1, described in detail elsewhere (unpublished data), 
also revealed a novel protein fold (  Fig. 3 a  ). Neither protein 
has a structural homologue in the Protein Data Bank data-
base. So although Evasin-1 and -3 are of similar size and 
function, they are completely unrelated at the amino acid 
sequence level, as well as in the secondary and tertiary struc-
ture (  Fig. 3, a and b  ). Although the mode of binding of 
Evasin-1 has been elucidated by the determination of the 
structure of the complex of Evasin-1 with CCL3 (unpub-
lished data), the structure of the Evasin-3 complex remains 
to be solved. If ticks produce two very diff  erent CHPBs, 
with very diff  erent selectivity profi  les, it is likely that they 
bind their substrates in very diff  erent way. The elucidation 
of the structure of the complex of Evasin-3 with its ligand(s) 
would thus greatly help to understand the selectivity of these 
diff  erent CHPBs. 
  Evasin-1 inhibits cell recruitment in vitro and in vivo 
  We have previously determined the binding affi   nities of Eva-
sin-1 for three chemokines by surface plasmon resonance, 
and we have extended these analyses to include the second 
form of CCL3, known as CCL3L1, as well as the murine ho-
mologues of CCL3 and CCL4 (  Table I  ). The K  d   value for 
0.05 nM CCL3L1 is similar to that determined for CCL3, in 
contrast to their very diff   erent potencies on CCR5 and 
CCR1 (  13  ). Importantly, the affi   nities for murine MIP-1      
and -1     , with K  d   values of 0.08 and 0.15 nM, respectively, 
are similar to those for the human chemokines, allowing sub-
sequent investigation of the antiinfl  ammatory properties of 
Evasin-1 in murine models. 
    Figure 3.         Crystal structures of Evasin-1 and -3  . Ribbon diagram of 
Evasin-1 (a) and Evasin-3 (b) with the amino acid sequence depicting 
residues in loops (green),      -helix (red), or     -sheet  (blue).   
    Figure 4.         Evasin-1 inhibits cell recruitment in vitro and in vivo  . 
(a) Inhibition of CCL3- (    ), CCL3L1- (    ) and CCL4-mediated (   )  chemotaxis 
of L1.2/CCR5 transfectants. The IC  50   values are 2 nM for CCL3, 0.17 nM for 
CCL3L1, and 4 nM for CCL4. Data are shown as the mean   ±   the SD as a 
percentage of maximal recruitment and are representative of three to fi  ve 
individual experiments. (b) Evasin-1 inhibits granulocyte recruitment in-
duced by CCL3 in mice. Evasin-1 was administered s.c. 45 min before the 
injection of 10   μ  g of CCL3 i.p. Cells in the peritoneal cavity were counted 
18 h after the injection of CCL3. One representative experiment of three is 
shown, with 8 mice per group. **, P   <   0.01 when compared with PBS-
treated group. Error bars represent the mean   ±   SEM.     2024 ANTIINFLAMMATORY SELECTIVE CHEMOKINE BINDING PROTEINS   | D  é  ruaz et al. 
administration of Evasin-1 alone had no chemoattractant ac-
tivity (unpublished data). 
  Evasin-1 shows antiinfl  ammatory activity in murine models 
of disease 
  The ability of Evasin-1 to prevent CCL3-/CCL4-dependent 
cellular recruitment translated into potent antiinfl  ammatory 
eff   ects in animal models of disease. Skin infl  ammation  in 
D6       /       mice sensitized with TPA gives rise to a phenotype 
closely resembling that of the human infl  ammatory skin dis-
order, psoriasis, and has been shown to be dependent on the 
induction of several CC chemokines, including CCL3 and 
CCL4, which are high-affi   nity ligands for D6 (  14  ). Evasin-1 
administration resulted in a signifi  cant reduction in skin in-
fl  ammation observed in these mice (  Fig. 6, a and b  ), but not 
complete abrogation as observed with an anti-TNF antibody.   
This is in accordance with our previous observations and 
assessed after 18 h. Evasin-1 showed dose-related inhibition of 
neutrophil recruitment with maximal activity at a dose of 10   μ  g 
(  Fig. 4 b  ), with little eff  ect on other cell types (not depicted). 
We therefore used this dose in subsequent studies. The in-
hibition of granulocyte recruitment by Evasin-1 was then 
further investigated in a murine model of a Th1-predominant 
delayed-type hypersensitivity and a Th2-predominant, late-
phase reaction. In the Th1 sensitization model using meth-
ylated BSA (mBSA), recruitment of granulocytes into the 
pleural cavity was signifi  cantly impaired (  Fig. 5 a  ).   Although 
the inhibition of neutrophil recruitment was most striking, 
inhibition of CD3  +   lymphocytes was also observed, although 
not of CD11b  +   monocytes as determined by FACS (unpub-
lished data). In the Th2 sensitization model, Evasin-1 inhib-
ited eosinophil recruitment induced by antigen challenge 
into the lungs of mice immunized with   S. mansoni   eggs. An 
analysis of naive mice by intravital microscopy demonstrated 
that Evasin-1 was able to block adhesion and emigration of 
leukocytes induced by injection of MIP-1      (  Fig. 5 b  ). Lastly, 
    Figure 5.         Evasin-1 inhibits cellular recruitment in models of Th1 
and Th2 infl  ammation.   (a) Evasin-1 inhibits granulocyte recruitment 
induced by antigen challenge of immunized mice in models of Th1-pre-
dominant delayed-type hypersensitivity and Th2-predominant late-phase 
response. In the Th1 model, 10   μ  g Evasin-1 was administered s.c. 45 min 
before intrapleural injection of 10   μ  g of mBSA in mice immunized with 
mBSA in Freund  ´  s complete adjuvant. Cells in the pleural cavity were 
counted 48 h after the injection of antigen. In the Th2 model, 10   μ  g Eva-
sin-1 was administered s.c. 45 min before and 24 h after the intratracheal 
injection of 10   μ  g of   S. mansoni   egg antigen in mice immunized with   S. 
mansoni   eggs. Cells in the bronchoalveolar lavage fl  uid were counted 24 
and 48 h after the injection of antigen. There were six mice per group in 
each experiment. *, P   <   0.05; **, P   <   0.01 when compared with PBS-
treated group. (b) Evasin-1 blocks adhesion and emigration of leukocytes 
induced by mMIP-1      as assessed by intravital microscopy performed in 
the cremaster vein of C57BL/6 mice. Evasin-1 was injected s.c. in the right 
scrotal skin 1 h before exteriorization. Normalized data were analyzed by 
one-way analysis of variance, and differences between groups were as-
sessed using Student-Newman-Keuls post-test. *, P   <   0.05; **, P   <   0.01. 
There were six mice per group in each experiment. Error bars represent 
the mean   ±   SEM.     
    Figure 6.         Evasin-1 inhibits cellular recruitment in an animal 
model of psoriasis.   (a) Dermal and epidermal thickness of the skin of WT 
and D6-defi  cient (KO) mice after a single cutaneous application of TPA. 
Evasin-1 (30   μ  g/mouse) and anti-TNF-      were given daily, and tissues 
were collected on day 4 for histological assessment. One representative 
experiment of three is shown, with eight mice per group. ***, P   <   0.001 
when compared with PBS-treated group. Error bars represent the mean   ±   
SEM. (b) Haematoxylin and eosin staining of sections from untreated skin 
of sham and TPA-injected D6-defi  cient mice treated with PBS, Evasin-1, 
or anti-TNF-     . Skin sections were obtained on day 4 after TPA application 
and are representative of 10 mice per group per experiment. Bars, 100   μ  m.     JEM VOL. 205, September 1, 2008 
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  indicates that although several CC chemokines are implicated 
in this model, targeting CCL3 and CCL4 is suffi   cient to ame-
liorate pathology. 
  CCL3 has previously been demonstrated to play a role in 
mediating pulmonary fi  brosis (  15  ). We therefore tested the 
eff  ect of Evasin-1 in a lung injury model induced by intratra-
cheal instillation of bleomycin. Mild or severe disease was in-
duced with 0.0625 or 0.125 U of bleomycin. Evasin-1 reduced 
lethality in both forms of the disease (  Fig. 7 a  ).   Reduction in 
lethality was associated with a decrease in neutrophil accumu-
lation at 2 and 8 d after bleomycin challenge (  Fig. 7 b  ), and a 
net decrease in the ensuing fi  brosis observed at later stages af-
ter the bleomycin challenge. Histopathological analysis of lung 
tissue confi  rmed decreased leukocyte infi  ltration in the lung 
(  Fig. 7 c  ), which was corroborated by a decrease in the num-
ber of CD3  +  CD4  +   and CD3  +  CD8  +   lymphocytes and GR1  +   
leukocytes in the bronchoalveolar lavage fl  uid of mice chal-
lenged with bleomycin. In bleomycin-instilled mice that did 
not receive Evasin-1, there was a considerable deterioration of 
normal pulmonary architecture with loss of alveolar structure 
and collagen deposition (  Fig. 7 c  ). Treatment with Evasin-1 
resulted in the preservation of lung architecture and a decrease 
in collagen deposition. Morphometric analysis of Gomori  ’  s 
trichrome  –  stained areas showed that Evasin-1 treatment re-
duced collagen deposition by 40%. 
  Evasin-3 is a potent inhibitor of neutrophil-
mediated infl  ammation 
  Evasin-3 has also been shown to have potent antiinfl  amma-
tory properties. In accordance with the nanomolar affi   nities 
observed by SPR analysis (  Table I  ), Evasin-3 produced in 
HEK293 cells and in   E. coli   inhibited binding of   125  I-CXCL8 
to CXCR1 with IC  50   values of 0.7 and 1 nM, respectively 
(  Fig. 8 a  ), demonstrating that glycosylation is not necessary 
for binding, similar to Evasin-1 (  11  ).   CXCL8-induced chemo-
taxis of neutrophils in vitro was inhibited by Evasin-3 with an 
IC  50   of 3.35 nM (  Fig. 8 b  ). In vivo, Evasin-3 inhibited KC-
induced neutrophil recruitment into the peritoneal cavity in 
a dose-dependent manner, with maximal inhibition at a dose 
of 1   μ  g per mouse (  Fig. 8 c  ). We also tested the ability of 
Evasin-3 to inhibit KC recruitment into the knee joint, and 
found it to be even more potent in this cavity (  Fig. 8 d  ). 
  Evasin-3 was then tested in a mouse model of antigen-in-
duced arthritis. In this model, rapid up-regulation of KC and 
MIP-2 precedes the recruitment of neutrophils into the knee 
joint. This is followed by CXCR2 up-regulation and TNF-      
production, culminating in synovial hyperplasia and infl  am-
matory hypernociception (  16  ). Administration of Evasin-3 
resulted in a 50% decrease in the total number of leukocytes 
in the synovial cavity (  Fig. 9 a  ).   The major leukocyte popula-
tions aff  ected were neutrophils, which were reduced by 70% 
in the knee joint (  Fig. 9 b  ). Moreover, Evasin-3 treatment 
signifi  cantly reduced the infl  ammatory hypernociception associ-
ated with this model (  Fig. 9 c  ), and interestingly, the treatment 
resulted in decreased local production of TNF-      (  Fig. 9 d  ). 
Intravital microscopy studies of the synovial microvasculature 
    Figure 7.         Evasin-1 inhibits lethality, cellular recruitment, and fi  -
brosis in a model of bleomycin-induced pulmonary injury  . (a) Evasin-1 
inhibits lethality associated with pulmonary instillation of bleomycin in 
C57BL/6 mice. Bleomycin was instilled intratracheally at doses of 0.0625 
U (circles) or 0.125 U (squares) and survival rates were evaluated for 25 d. 
PBS (open symbols) or Evasin-1 (10   μ  g per animal; closed symbols) were 
administered s.c. 45 min before and every 12 h after initial bleomycin 
instillation. There were 12 mice per group in each experiment. *, P   <   0.05 
when comparing PBS- and Evasin-1  –  treated animals at 0.125 U. (b) Eva-
sin-1 inhibits neutrophil recruitment induced by bleomycin. Neutrophil 
recruitment was evaluated at 2 and 8 d after bleomycin (0.125 U) and 
Evasin-1 (10   μ  g per animal) was administered s.c. 45 min before and every 
12 h after initial bleomycin instillation. There were six mice per group in 
each experiment. *, P   <   0.05 when compared with the PBS-treated group. 
Error bars represent the mean   ±   SEM. (c) Evasin-1 inhibits pulmonary 
infl  ammation and fi  brosis induced by instillation of bleomycin. Hema-
toxylin and eosin  –   (top) and Gomori  ’  s trichrome  –  stained (bottom) sec-
tions from animals instilled with sodium chloride (0.9% NaCl, 25   μ  l) or 
bleomycin (0.125 U). Evasin-1 (10   μ  g per animal) was administered as 
previously described and lungs were removed on day 16. Bars: (top) 100   μ  m; 
(bottom)  50   μ m.   2026 ANTIINFLAMMATORY SELECTIVE CHEMOKINE BINDING PROTEINS   | D  é  ruaz et al. 
setting. Consistent with the aforementioned fi  ndings, histo-
pathological analysis of tissue demonstrated overall inhibition 
of leukocyte infl  ux into the joint and periarticular tissues, 
  decreased edema, and decreased synovial hyperplasia (  Fig. 9, 
f and g  ). 
  Finally, we tested both proteins in the same recruitment 
model, chemokine-induced neutrophil in the knee joint, at 
the doses used in the disease models, and both Evasins were 
able to completely inhibit the recruitment induced by their 
showed that administration of Evasin-3 prevented the adhe-
sion of leukocytes to the synovial endothelium (  Fig. 9 e  ), 
providing a direct demonstration of the effi   cacy of Evasin-3 
in the prevention of neutrophil infl  ux in an infl  ammatory 
    Figure 8.     Evasin-3 inhibits cell recruitment in vitro and in vivo  .    
(a) Inhibition of   125  I-CXCL8 binding to CXCR2 by Evasin-3 produced in 
HEK293 cells (    ) and by Evasin-3 produced in   E. coli   (   ). (b) Inhibition of 
CXCL8 induced neutrophil chemotaxis in vitro. (c) Inhibition of KC induced 
neutrophil recruitment into the peritoneal cavity (c) and into the knee 
joint (d). There were six mice per group in each experiment. **, P   <   0.01; 
***, P   <   0.001 when compared with PBS-treated group. Error bars repre-
sent  the  mean   ±   SEM.   
    Figure 9.     Evasin-3 inhibits neutrophil recruitment and ameliorates 
infl  ammation and functionality in a mouse model of antigen-
induced arthritis.   (a – g)  Reduction  of  infl  ammation in mBSA induced 
arthritis by Evasin-3 (1   μ  g per animal). (a) Inhibition of total cell accumu-
lation in the synovial cavity. (b) Inhibition of neutrophil infi  ltration into 
the knee joint. (c) Reduction of hypernociception induced by intraarticular 
antigen challenge of immunized mice. (d) Reduction of TNF-      production 
in periarticular tissues. (e) Inhibition of adhesion of leukocytes to synovial 
microvessels as assessed by intravital microscopy. (f and g) Histological 
evaluation of the tissue sections form the knee joint. All parameters were 
evaluated 24 h after antigen challenge, and there were 6 mice per group 
in each experiment. *, P   <   0.05; **, P   <   0.01. Error bars represent the 
mean   ±   SEM. Bars, 100   μ  m.     JEM VOL. 205, September 1, 2008 
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respective ligand (  Fig. 10 a  ).   The eff  ect of the Evasins was 
shown to be specifi  c to chemokine inhibition because nei-
ther was able to inhibit neutrophil recruitment mediated by 
zymosan (  Fig. 10 b  ), which has been shown to mediate its ef-
fects through chemoattractants such as C5a (  17  ) and LTB4 
(  18  ). As both Evasins inhibit neutrophil recruitment medi-
ated by diff  erent chemokines, we tested them head to head in 
the same model, intestinal ischemia. As shown in   Fig. 10 c  , 
Evasin-3 was more effi   cacious, showing signifi  cant reduction 
in lethality at doses of 1 and 0.1   μ  g, whereas Evasin-1 only 
showed signifi  cant effi   cacy at the 30   μ  g dose, with only a slight 
eff  ect seen at the 10   μ  g dose. 
    DISCUSSION   
  Since the identifi  cation of the fi  rst members of chemokine 
family over 20 yr ago, it has become clear that the interaction 
of these small proteins with their cognate receptors are im-
portant targets for therapeutic intervention in several infl  am-
matory, autoimmune, and infectious diseases. Indeed, there 
are currently many intense drug discovery programs in this 
area. Yet, although there are numerous reports of the effi   cacy 
of small molecule antagonists (  19  –  21  ), neutralizing antibodies 
(  22, 23  ), and other antagonists (  24  ) in animal models of dis-
ease, it has proven to be more of a challenge to translate these 
molecules into medicines in the clinic. Although many mol-
ecules are currently progressing into late-stage clinical trials, 
it is possible that alternative approaches may be needed to 
successfully target the chemokine  –  chemokine receptor inter-
action. Ticks have evolved natural antichemokine strategies 
in the guise of CHPBs, which are able to counter the host 
defense systems against parasites. Unraveling the molecular 
nature of these CHBPs may produce novel insights into the 
design of therapeutically useful chemokine blocking agents. 
  In this study, we describe the cloning and characteriza-
tion of a family of CHPBs from tick saliva. In vitro character-
ization of the family members identifi  ed to date indicates that 
these CHBPs are considerably diff  erent from the known viral 
CHPBs in terms of chemokine selectivity. Many of the viral 
CHBPs such as myxoma virus M-T7 and murine gammaher-
pes virus 68 M3 and the recently identifi  ed   S. mansoni   (for 
review see [  3  ]) tend toward broad selectivity, binding both 
CC and CXC chemokines; the Evasins described here have 
restricted selectivity. In the studies presented here, we have 
shown that Evasins are able to bind and inhibit specifi  c che-
mokines in vitro, and inhibit leukocyte recruitment induced 
by their respective ligands in simple models of leukocyte re-
cruitment in mice. Furthermore, the antiinfl  ammatory prop-
erties of Evasins were confi  rmed mechanistically by intravital 
microscopy where their administration both in naive and in-
fl  amed mice abrogated leukocyte adhesion to, and transmi-
gration across, the endothelium. Together, these experiments 
clearly demonstrated the potential of Evasins to prevent leu-
kocyte recruitment. 
  We evaluated the Evasins in more complex animal mod-
els of human disease. Evasin-1, which is highly selective for 
CCL3 and CCL4, reduced symptoms in a murine model of 
    Figure 10.         Direct comparison of Evasin-3 and -1  . (a) Inhibition of 
chemokine-induced neutrophil recruitment into the knee joint induced by 
chemokine (a) or by Zymozan (b). Evasin-1 (10   μ  g) and Evasin-3 (1   μ  g) 
were administered 30 min into the knee joint before the administration of 
300 ng mMIP-1      or 30 ng KC, respectively, or 30   μ  g Zymosan. Cells in the 
joint were counted 6 h after the injection of stimuli. There were fi  ve mice 
per group in each experiment. **, P   <   0.01; ***, P   <   0.001 when compared 
with PBS-treated group. (c) Prevention of ischemic reperfusion. Evasin-1 
and -3 were administered s.c. at the doses indicated 30 min before the 
reperfusion of the occluded superior mesenteric artery. There were seven 
to eight mice in each experimental group. **, P   <   0.01 when compared 
with PBS-treated group. Error bars represent the mean   ±   SEM.     2028 ANTIINFLAMMATORY SELECTIVE CHEMOKINE BINDING PROTEINS   | D  é  ruaz et al. 
that recruit these cell types; Evasin-1 (in rodents) and Evasin-
3 prevent neutrophil accumulation, and preliminary results 
indicate that Evasin-4 binds the eosinophil-recruiting che-
mokines CCL5 and CCL11. Moreover, their selectivity pro-
fi  les highlight the issue of species specifi  city in the chemokine 
system. The common brown dog tick feeds on dogs and 
other domestic animals, as well as rodents, deer, and humans; 
thus, in spite of chemokine selectivity, one would expect 
species cross-reactivity. We have performed our studies using 
human chemokines, and in some cases, their murine coun-
terparts, and have shown that the Evasins are able to bind to 
chemokines in both species. The cross species reactivity may 
be an advantage in the development of these molecules 
as potential therapeutic agents, as one of the pitfalls in the 
development of small molecule antagonists of human che-
mokine receptors has been their lack of cross-reactivity with 
rodent chemokine receptors, which has hampered testing in 
animal models of disease, PK/PD, and toxicological studies. 
However, results obtained from in vivo testing of Evasins still 
needs to be interpreted with caution, as there are known dif-
ferences in specifi  c chemokine receptor expression on im-
mune cells between the human and murine system, particularly 
on neutrophils. In humans, the principal mediators of neu-
trophil recruitment are CXC chemokines 1 –  8, acting through 
CXCR2, and CXCL8, which acts on both CXCR1 and 
CXCR2. On the contrary, recruitment of murine neutro-
phils is mediated by both CCR1 and CXCR2, and perhaps 
also the recently identifi  ed murine CXCR1 (  32  ), although 
little is known about the role of the latter in vivo. However, 
CCR1 is not normally expressed on human neutrophils, al-
though it can be induced by IFN-      (  33  ). Interestingly, CCL3 
has been shown to recruit neutrophils when injected into 
human skin (  34  ). Thus, Evasin-1 shows activity against CCL3-
mediated neutrophil recruitment rather than monocyte recruit-
ment in the mouse, whereas the ability of Evasin-3 to recruit 
neutrophils is predictable from its binding profi  le. It should 
also be noted that although Evasin-1 has a higher affi   nity for 
its ligands than Evasin-3, the latter is more effi   cacious in the 
murine models we have tested. 
  Saliva from ticks harvested at diff  erent times during their 
feeding periods has diff  erential chemokine inhibitory activity, 
suggesting that diff  erent CHPBs are produced at diff  erent times 
during feeding, with the aim of selectively inhibiting specifi  c 
cell populations (  35  ). It is possible that the most potent inhibi-
tor of neutrophil recruitment produced by the tick is Evasin-3, 
whereas Evasin-1 may be produced to inhibit (later) monocyte 
recruitment in nonrodent hosts, as well as T lymphocytes, as 
was observed in the bleomycin lung infl  ammation model. Un-
fortunately, the expression profi  le of chemokine receptors on 
leukocytes in the dog, which although its name implies is the 
preferred host, may simply be the most easily available food 
source, is unknown and hence we cannot substantiate this 
hypothesis. Lastly, the availability of recombinant Evasin-4 will 
enable us to address the ability of this CHBP to modulate eo-
sinophil traffi   cking because both CCL5 and CCL11 have been 
extensively described to recruit this cell type. 
skin infl   ammation that resembles psoriasis in humans, in 
which several CC chemokines are implicated (  14  ). Because 
both Evasin-1 and -3 were shown to prevent neutrophil in-
fl  ux, they were subsequently tested in disease models in which 
neutrophils have previously been shown to play an important 
role. Thus, in the CCL3-dependent bleomycin-induced lung 
injury, Evasin-1 reduced leukocyte infl  ux, fi  brosis, and le-
thality, an eff  ect qualitatively and quantitatively similar to ex-
periments in CCL3-defi   cient mice (  15, 25  ). Blockade of 
CXCR2 has been reported to prevent leukocyte infl  ux and 
joint damage in several models of experimental arthritis in rats 
and mice (  26, 27  ). Evasin-3, which binds to both human and 
murine CXCR2 ligands, prevented neutrophil infl  ux  into 
the joint in a model of antigen-induced arthritis. Interest-
ingly, this treatment also prevented the local production of 
TNF-     , a cytokine that has been shown to play an important 
role in the pathogenesis of arthritis, and which is associated 
with hypernociception or infl  ammatory pain in experimental 
animals. Indeed, blockade of TNF-      with biologicals has 
been successful in the treatment of rheumatoid arthritis and 
other rheumatologic conditions (  28, 29  ). 
  Our initial expectation was that identifi  cation of CHBPs 
in primitive eukaryotic species such as ticks may allow us to 
identify orthologues in mammalian genomes, based on either 
primary sequence or on the three-dimensional folds of the 
CHBPs. However, extensive searching of public databases at 
both the amino acid and nucleotide sequence level have in-
dicated that there are no human or mammalian orthologues 
or structural counterparts to the Evasins. On the other hand, 
by blast analysis of the available tick sequences, we were able 
to identify an EST in the cattle tick   Boophilus microplus   that 
may encode a potential orthologue of Evasin-1 (30% identity 
over 95 amino acids). Although the level of identity is low, it 
is comparable to that seen between Evasin-1 and -4. We are 
now in the process of producing the   Boophilus microplus   pro-
tein to verify if it is indeed a CHPB. It is likely that additional 
CHPBs from other species of tick will be identifi  ed in due 
course through homology searching, as the number of tick 
EST sequences appearing in public databases increases from 
tick salivary gland transcriptome sequencing projects. 
  Thus, it appears that ticks have specifi  cally  developed 
novel protective CKBPs as they adapted to their chemokine-
producing vertebrate hosts. Although mammals do have mole-
cules that can bind and block chemokine function, they are 
molecularly and structurally distinct from the Evasins. For 
example, the atypical chemokine receptors such as D6, CCX-
CKR, and Duff  y (  30, 31  ) are nonsignaling GPCRs that ap-
pear to be able to function as mammalian equivalents of the 
soluble CKBPs expressed by pathogens and parasitic worms. 
This suggests that, contrary to viral chemokines and chemo-
kine receptors that have been hijacked from the mammalian 
genome, pathogens have evolved CKBPs through a   “  conver-
gent  ”   evolution mechanism. 
  The leukocytes involved in the fi  rst line of defense against 
pathogens and parasites are neutrophils and eosinophils. The 
CHBPs described here specifi  cally inhibit the chemokines JEM VOL. 205, September 1, 2008 
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coating the chemokines on a CM4 chip (BIAcore), with RNaseA as nega-
tive protein control, and tick saliva injected after a 10- or 25-fold dilution in 
HBS-P buff  er (BIAcore) for equilibration and 10 mM glycine-HCl, pH 2.5, 
for regeneration. The sensograms were analyzed using BIAcore 3000 evalu-
ation software after subtraction of nonspecifi  c binding to the control protein. 
Retentate chromatography SELDI mass spectrometry (RC-SELDI-TOF-
MS) was used to detect distinct CHPBs in the tick saliva. CCL5, CCL3, and 
CXCL8 or the control protein, equine myoglobin, were diluted to 0.1   μ  g/  μ  l 
in PBS and immobilized onto separate spots of a PS-20 ProteinChip array 
according to the manufacturer  ’  s instructions (Ciphergen Biosystems, Inc.). 
After blocking and washing of the array, frozen tick saliva was diluted fi  ve-
fold in PBS and 5   μ  l was applied to each spot and incubated for 2 h at room 
temperature. After washing, the matrix, sinapinic acid, was dried onto each 
spot on the array and mass analysis was performed by SELDI-TOF-MS, us-
ing a calibrated ProteinChip Biology System IIc reader. Spectra were gener-
ated using an automated protocol and a positive ion mode with a laser 
intensity of 220 and defl  ector sensitivity of 10. The mass optimization range 
was set between 10 and 50 kD, with a mass focus set to 18 kD. To obtain 
quantitative data, the mass spectra from each spot were accumulated from 
155 laser shots over 31 diff  erent and nonoverlapping positions. 
  Molecular cloning.     Expression cloning was performed by transient trans-
fection of HEK293 cells with a cDNA library constructed from the salivary 
glands of   R. sanguineus  , as previously described (  11  ). Supernatants from 
transfected cells were screened using two cocktails of radiolabeled [I-  125  ] 
CXCL8, IL-1, and IL-2, or CCL5, CCL11, and CXCL10, respectively, fol-
lowed by cross-linking and analysis by SDS-PAGE. After deconvolution of 
the cDNA pools and sequencing of the positive clones, a C-terminal 6His-
tagged version of the cDNA encoding the relevant CHBP was subcloned 
into the mammalian cell expression vector pEAK12d (Edge Biosystems) us-
ing the Gateway cloning system (Invitrogen). The protein was purifi  ed by 
Ni-chelate chromatography after transient expression in 500 ml HEK293 
cultures. The cDNA encoding Evasin-3 was subcloned into the pET30a 
vector (Novagen) for expression in   E. coli   strain BL21(DE3) and produced in 
a 5-liter fermenter. The protein was purifi  ed from the cytosolic fraction by 
cation exchange chromatography and size exclusion chromatography. 
  In vitro characterization.     The selectivity of Evasin-3 was determined by 
SPR, as previously described (  11  ). Kinetic measurements were performed to 
determine the binding constants. The kinetic values k  a   and k  d  , which are 
shown in   Table I  , are the mean of three independent experiments performed 
in triplicate on three diff  erent chips. The affi   nity constant K  d   was calculated 
from theses mean values. Equilibrium competition receptor binding assays 
were performed using CHO/CXCR1 transfectants using   125  I-CXCL8, as 
previously described (  39  ). Inhibition of chemotaxis in vitro was measured 
using L1.2/CCR5 transfectants for Evasin-1 or neutrophils purifi  ed from 
buff  y coats as previously described (  40  ). 
  In vivo experiments.     Male BALB/c or C57BL/6 mice (18  –  22 g) were 
housed in a temperature-controlled room and had free access to food and 
water. All experiments received prior approval by the local animal ethics 
committee. To test the eff  ect of Evasin-1 on cellular recruitment in vivo, 
mice were administered 0.01  –  10   μ  g Evasin-1 in 200   μ  l PBS s.c. 45 min be-
fore the administration of 10   μ  g CCL3 or 0.3   μ  g mMIP-1      in 200   μ  l PBS 
i.p. Cell recruitment was evaluated 18 h after the stimulus. To test the eff  ect 
of Evasin-3 on neutrophil recruitment, KC (30 ng/cavity) was injected into 
the peritoneal cavity or the left knee joint of the mouse and recruitment was 
evaluated 4 h later. Evasin-3 (0.01  –  1   μ  g/mouse) was given s.c. 45 min be-
fore KC administration. 
  Intravital microscopy was performed in unbranched cremasteric venules 
(25  –  40   μ  m in diameter) of C57BL/6 mice, as previously described (  41  ). For 
each experiment, 0.3   μ  g of human CCL3 in 100   μ  l of PBS was administered 
locally by s.c. injection beneath the right scrotal skin, 1 h before exterioriza-
tion. To test inhibition, a solution of Evasin-1 (10   μ  g per animal) plus CCL3 
(0.3   μ  g) in 100   μ  l PBS was prepared 15 min before intrascrotal injection. 
  A striking feature of these proteins is their small size. Both 
viral and mammalian chemokine and cytokine binding pro-
teins have been shown to be much larger, generally     30  –  40 
kD. On the other hand,   R. sanguineus   has developed very 
small, highly selective CHBPs. Interestingly, these proteins 
are similar in size, if not smaller, than the naturally occurring 
single chain antibodies such as shark V-NAR domains (15 
kD) or camelid VhH domains (15 kD). Large eff  orts are cur-
rently being undertaken to produce small proteins known as 
nanobodies, minibodies, or microproteins, created by ratio-
nal design in silico, which will mimic the binding properties 
of natural single-domain antibodies (  36  ). The two proteins 
described here represent highly potent, miniaturized scaff  olds 
that have evolved to selectively bind certain proteins, pivotal 
to the immune response, and which could be useful in the 
creation of new scaff  olds, paving the way for development of 
these molecules as novel antiinfl  ammatory agents. 
  One of the important issues surrounding the use of any 
protein as a potential therapeutic agent concerns immunoge-
nicity, which could be particularly pertinent for nonhuman 
proteins. There are already examples of xenoproteins in the 
clinic (  4, 37  ) and others are entering clinical trials. However, 
as these proteins are generally administered in a single dose 
for acute indications, potential immunogenicity is not a ma-
jor concern. However, treatment of infl  ammatory and auto-
immune diseases with therapeutic proteins such as IFN-      or 
antibodies, e.g., Raptiva and Etanercept, requires chronic ad-
ministration, and even fully human proteins can elicit an an-
tibody response that may reduce the effi   cacy of the treatment. 
By their very nature, antiinfl  ammatory proteins in tick saliva 
do not appear to be immunogenic. It is still unclear if this is 
entirely caused by the inhibition of immune cell recruitment 
to the attachment site, or indeed whether the protein struc-
ture itself or through glycosylation minimizes exposure of 
antigenic epitopes. Furthermore, bioinformatic analysis of T 
cell epitopes on Evasins using software developed by Biova-
tion (EMD Serono) revealed that the tick Evasins have rela-
tively few potential immunogenic epitopes compared with 
other therapeutic proteins currently in the clinic, such as 
IFN-     . It is also interesting to note that only 1 mouse out of 
6 treated for 25 d had an IgG response to Evasin-1 (unpub-
lished data). So although immunogenicity in the murine system 
will not predict the outcome in humans, further evaluation of 
Evasins in preclinical models is warranted for their develop-
ment as potential protein therapeutic agents. 
  Lastly, the mining of the salivary transcriptomes of the 
numerous species of ticks will provide a wealth of potential 
immunomodulatory molecules, and other pharmacologically 
relevant proteins, which will provide novel molecular en-
tities to enrich the current repertoire of biotherapeutics in the 
future (  5, 38  ). 
    MATERIALS AND METHODS   
  Biochemical analysis of antichemokine activity in saliva.     Collection 
of   R. sanguineus   saliva, inhibition of receptor binding and the cross-linking 
assay were performed as previously described (  11  ). SPR was performed by 2030 ANTIINFLAMMATORY SELECTIVE CHEMOKINE BINDING PROTEINS   | D  é  ruaz et al. 
lung injury, antigen-induced arthritis, and ischemia and reperfusion injury 
experiments were evaluated and approved by the Animal Ethics committee of 
the Universidade Federal de Minas Gerais, Brazil. 
  Histological assessment.     Sections were graded as previously described (  48  ). 
In brief, the histological score (0  –  8) was the sum of the synovial hyperplasia, 
cellular exudate, and cartilage depletion/bone erosion ranging from 0 (nor-
mal) to 3 (severe), and the degree of synovial infi  ltrate ranging from 0 (nor-
mal) to 5 (severe). 
  Statistical analysis.     All results are presented as the mean   ±   SEM. Normal-
ized data were analyzed by one-way ANOVA, and diff  erences  between 
groups were assessed using the Student-Newman-Keuls post test. A P value   <   
0.05 was considered to be signifi  cant. 
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